A5047747904- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Nutrition, Genetics, and Disease
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases
- Advances in Oncology and Radiotherapy
- Genetic factors in colorectal cancer
- Pleural and Pulmonary Diseases
- Pharmaceutical Practices and Patient Outcomes
- Cancer-related Molecular Pathways
Instituto de Salud del Estado de México
2017-2025
Eastern Cooperative Oncology Group
2024
Universidad Politécnica Metropolitana de Hidalgo
2021
Tecnológico de Monterrey
2008-2019
Instituto Nacional del Cáncer
2019
Hospital de Clínicas
2019
Scottish Intercollegiate Guidelines Network
2019
Universidad Autónoma del Estado de México
2019
Research Institute Hospital 12 de Octubre
2019
Hospital de Clínicas de Porto Alegre
2019
An earlier analysis of this phase 3 trial showed that the addition a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided greater benefit with regard progression-free survival than alone in premenopausal or perimenopausal patients advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report results protocol-specified interim key secondary end point overall survival.We randomly assigned receive either...
Abstract Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). The median OS was not reached ribociclib arm protocol-specified final analysis; we hence performed an exploratory additional outcomes analysis extended follow-up (median, 53.5 months)....
Abstract Background Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Patients and Methods Medical records with documented metastatic UC treated by as second-line therapy were retrospectively collected from 88 institutions 23 countries. assessed for overall survival (OS),...
This analysis evaluated the genomic landscape of premenopausal patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer association genetic alterations response to ribociclib in phase III MONALEESA-7 trial.Premenopausal were randomly assigned 1:1 receive endocrine therapy plus or placebo. Plasma collected at baseline was sequenced using targeted next-generation sequencing for approximately 600 relevant genes. The circulating tumor...
LBA1008 Background: The phase III MONALEESA-7 study (NCT02278120) is the first dedicated trial of endocrine therapy (ET) ± a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in premenopausal patients (pts) with hormone receptor–positive (HR+)/HER2− ABC. met its primary endpoint significantly longer progression-free survival (PFS) ribociclib (RIB; CDK4/6 inhibitor) + ET vs placebo (PBO) (median, 23.8 13.0 mo; HR, 0.55; P < 0.0001; Tripathy D, et al. Lancet Oncol. 2018). Methods:...
Abstract Background: MONALEESA-7 (NCT02278120), the first large randomized phase III clinical trial dedicated to investigating a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus ET vs + placebo (PBO) in pre- or perimenopausal patients with HR+/HER2− ABC, previously demonstrated statistically significant improvement OS addition of ribociclib (RIB) PBO (median, not reached 40.9 months; HR, 0.71 [95% CI, 0.54-0.95]; P = .00973; Im SA, et al. N Engl J Med. 2019). This concluded...
PURPOSE Metastatic urothelial carcinoma (mUC) poses a challenge to health care systems, given its treatment complexity and mortality. We aimed describe the characteristics, patterns, survival outcomes of Mexican patients with mUC. METHODS A retrospective study was conducted across eight centers for adults mUC from January /2001 December 2021. recorded medical history, eligibility first-line platinum therapy, lines received, access novel drugs. Descriptive statistics were used analysis,...
518 Background: Clinical markers of response and outcome in metastatic renal cell carcinoma (mRCC) are lacking. Low hemoglobin (Hb) is associated with poor outcomes the IMDC risk score. Hb levels also appear to be mRCC VEGFI monotherapy, although this relationship nuclear. This study evaluates role increases as a predictive biomarker clinical outcomes. Methods: Patients advanced RCC treated VEGF receptor tyrosine kinase inhibitors (TKIs) first-line therapy were identified. Hemoglobin...
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, sex hormonal profile, intrinsic differences local systemic immune systems urobiome composition. Existing literature data pan-cancer context reveal contradictory results, real-world evidence urothelial carcinoma (UC) is lacking. This was real-world, multicenter, international, observational study...
Abstract Background:Endocrine therapy (ET) with ovarian function suppression is an established first-line treatment for pre- and peri-menopausal women hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Addition of ribociclib (orally bioavailable, selective cyclin-dependent kinase [CDK] 4/6 inhibitor) to ET prolonged progression-free survival (PFS) in a Phase III trial postmenopausal HR+, HER2– ABC (MONALEESA-2). Here we...
Resumen. El cáncer de pulmón es una las principales causas mortalidad alrededor del mundo. Su historia natural, con la manifestación síntomas en etapas avanzadas y el retraso su diagnóstico hacen que gran proporción pacientes se diagnostiquen estadios tardíos enfermedad, lo hace muy complicado tratamiento exitoso misma. De esto deriva importancia dar origen a recomendaciones basadas evidencia para soportar toma decisiones clínicas por parte los grupos interdisicplinarios encargan manejo este...
Breast cancer is the most frequently diagnosed malignancy in women, and comorbidities like hypertension obesity diminish their quality of life negatively affect response to chemotherapy. Furthermore, inulin supplementation associated with reduction cardiovascular diseases (CVD) risk. To determine whether prevents elevation blood pressure women breast undergoing neoadjuvant therapy cyclophosphamide doxorubicin. This was a randomized, double-blind placebo controlled trial which included...
To determine prevalence trends of using Wood as the Main Cooking Fuel (WMCF) in Mexico and household characteristics that predict its use.Estimates were obtained from 1990, 2000 2010 censuses a national survey performed 2012 2013.In 2012-2013, 9.5% 66 321 surveyed households 10.9% their 252 011 residents used WMCF. Prevalence was higher rural (40.5%) than urban areas (1.5%), p<0.0001. From 1990 to 2013 wood use decreased by 53% overall 28.6% areas, gas increased respectively 17.5 52.7%....
Chromosomal translocation resulting in the fusion between echinoderm microtubule-associated protein-like 4 (EML4) gene and anaplastic lymphoma kinase ( ALK) was recently identified as a novel genetic alteration subset of non-small cell lung cancer (NSCLC). EML4– ALK translocations are rare events associated with specific clinicopathological features, such never or light smoking history, young age adenocarcinoma signet ring acinar histology. Reports suggest arrangements mutually exclusive...
Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and histologically similar to Breast Cancer. We report what we believe be first case in literature metastatic salivary duct carcinoma (SDC) with objective response tamoxifen aromatase inhibitors, achieving long-term stability disease no associated toxicity. A 70-year-old female was referred our institution for treatment painless nodular lesion scalp, localized frontal region cranium. biopsy taken tested...
Background Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There a lack of information about the clinical and pathological features related survival in Latin American population. Methods The MeSO‐CLICaP registry identified 302 patients advanced MPM diagnosed treated between January 2008 March 2016. Cox model was applied to determine variables survival. A random forest tree built predict response first‐line chemotherapy among patients. Results...
Abstract Background: In the MONALEESA (ML) trials, addition of ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) prolonged progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). RIB was generally well tolerated, adverse events (AEs) managed effectively by dose modifications. Here we present efficacy data for RIB-based regimens interest proposed indication (i.e. a non-steroidal...
Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced NSCLC received brigatinib second or line of Mexico Colombia. The primary end point was progression-free survival (PFS); secondary time treatment discontinuation (TTD). Results: At a median follow-up 9.3 months, the PFS...
562 Background: Oral IRI offers patient (pt) convenience and provides protracted drug exposure. Following reported activity of IV (Camptosar) in refractory MBC (Perez et al. JCO 22:2849), this study evaluates efficacy safety two oral schedules pts with after failure prior anthracycline(A), taxane(T), capecitabine(C). Methods: Multicenter, 2-arm, randomized phase 2 Simon 2-stage design. Eligible have histologically confirmed, measurable MBC. Failure A, T or C includes progression during...
Abstract Introduction Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of disease. The LATAM subset real‐world, global KINDLE study reported treatment patterns and clinical outcomes for from pre‐immuno‐oncology era. Methods was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru Uruguay) stage NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 December 2017....
1018 Background: The Phase III MONALEESA-7 study (NCT02278120) is the first dedicated trial of endocrine therapy (ET) ± a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in premenopausal patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) ABC. demonstrated that addition ribociclib (RIB) to nonsteroidal aromatase (NSAI) or tamoxifen (TAM) + goserelin (GOS) significantly extended progression-free survival (PFS; hazard ratio [HR] 0.55;...
628 Background: A pilot, open-label, multicenter, multinational, randomized, parallel group, comparative study was conducted in post-menopausal women with advanced ER/PgR + breast cancer (BC) and at least one visceral lesion (liver or lung) measurable using RECIST criteria Methods: Subjects had progressed during prior antiestrogen treatment, ≤ 12 months since adjuvant treatment. were randomized 1:1 to either exemestane (E) (25 mg po qd) anastrozole (A) (1 qd). Prior treatment chemotherapy...